Skin Infection News and Research

RSS

Forest Laboratories second quarter net sales increase 7.7% to $1,037.3 million

Forest Laboratories, Inc., an international pharmaceutical manufacturer and marketer, announced that diluted earnings per share equaled $1.00 in the second quarter of fiscal 2011.

19 Oct 2010

NovaBay to present two poster presentations at IDSA Annual Meeting

NovaBay Pharmaceuticals, Inc. a clinical stage biotechnology company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic-resistant infections, announces that it will deliver two poster presentations on its compounds at the 48th Annual Meeting of the Infectious Diseases Society of America (IDSA).

15 Oct 2010

Persimmon Scientific to showcase antimicrobial nursing pads, hypoallergenic diaper liners at 8th ABC Kids Expo

Persimmon Scientific, Inc., dedicated to integrating technical and engineered fabrics into innovative, patentable medical products that promote skin comfort and improve quality of life, will be exhibiting at the First Timers Pavilion Booth #4439 and New Products Showcase at the upcoming ABC Kids Expo, the primary trade show for the juvenile products industry.

11 Oct 2010

Isogenica, NovaBiotics to accelerate the development of peptide anti-infective technology

Isogenica Ltd, today announced that it has entered into a collaboration agreement with NovaBiotics, a leading clinical-stage biotechnology company to fast-track the development of NovaBiotic's platform peptide anti-infective technology.

6 Oct 2010

Islamic Relief USA provides $20 million medical aid to Pakistan

Islamic Relief USA (IR USA), a non-profit relief and development organization based in metro-D.C., announced today that it has delivered a $20 million aid shipment of medicine to Pakistan.

22 Sep 2010

NovaBay Pharmaceuticals delivers poster presentations on Aganocide compound at ICAAC Conference

NovaBay Pharmaceuticals, Inc., a clinical stage biotechnology company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic resistant infections, delivered four poster presentations on its Aganocide compounds at the 50th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Boston, MA.

16 Sep 2010

Rib-X Pharmaceuticals presents positive preclinical data for delafloxacin at ICAAC Conference

Rib-X Pharmaceuticals, Inc., a development-stage antibiotics company with a broad product pipeline based on its innovative discovery platform, today announced the presentation of positive preclinical data for delafloxacin in four poster sessions at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC).

14 Sep 2010

NovaBay Pharmaceuticals to deliver new data on Aganocide compounds at ICAAC Conference

NovaBay Pharmaceuticals, Inc., a clinical stage biotechnology company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic-resistant infections, will deliver four poster presentations on its compounds at the 50th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC).

9 Sep 2010

Lytix Biopharma granted Hungarian approval for Lytixar Phase IIa clinical trial in Gram positive skin infections

The Norwegian pharmaceutical company Lytix Biopharma AS today announces the approval in Hungary to commence a Phase IIa clinical trial with Lytixar (LTX-109) treatment of skin infections caused by Gram positive bacteria.

2 Sep 2010

Neutralizing key toxin associated with Staph aureus bacteria reduces severity of skin and soft-tissue damage

Scientists from the National Institutes of Health and University of Chicago have found a promising treatment method that in laboratory mice reduces the severity of skin and soft-tissue damage caused by USA300, the leading cause of community-associated Staphylococcus aureus infections in the United States.

2 Sep 2010

Media examine floods' impact in Pakistan

News outlets reported on the effects of major flooding in Pakistan and described the situation on the ground.

2 Sep 2010

Scientists report frog skin contains new genera of antibiotics

Kissing a frog won't turn it into a prince except in fairy tales but frogs may be hopping toward a real world transformation into princely allies in humanity's battle with antibiotic-resistant infections that threaten millions of people worldwide. Scientists today reported that frog skin contains natural substances that could be the basis for a powerful new genre of antibiotics.

30 Aug 2010

Diarrhea, skin diseases increase among children in flood-affected areas of Pakistan: Survey

World Vision says assessments conducted over the last few days near the towns of Muzaffar Garh and Kot Addo in Punjab paint a bleak picture of the impact of the flooding. The Christian humanitarian organization says its reports from Sukkur in the Sindh Province are equally dire. Contaminated water, cramped living conditions and a lack of sanitation are contributing to a rapid increase in cases of diarrhea and skin diseases in children.

25 Aug 2010

NanoViricides' anti-Herpes drug candidates demonstrate significant efficacy in cell culture studies

NanoViricides, Inc., reports that its anti-Herpes drug candidates demonstrated significant efficacy in the recently completed cell culture studies. The studies were performed in the laboratory of Dr. Ken Rosenthal at Northeastern Ohio Universities Colleges of Medicine and Pharmacy.

16 Aug 2010

NovaBay second-quarter net loss increases to $1.2 million

NovaBay Pharmaceuticals, Inc., a clinical stage biotechnology company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic-resistant infections, today reported second quarter financial results and highlighted the clinical progress of its in-house programs.

13 Aug 2010

Hospital staph infection rate drops as national prevention effort steps up

The rate of drug-resistant staph hospital-acquired infections has dropped as the U.S. has stepped up prevention efforts to fight the deadly condition, The Associated Press reports. "The decline was seen in a federal study of methicillin-resistant staph, or MRSA. The bug often causes only a boil or skin infection. But researchers in the study focused on invasive cases that can become deadly, invading the bloodstream, flesh, lungs and bones. Researchers found that in nine metro areas, cases of MRSA (MUR'-suh) fell about 16 percent between 2005 and 2008.

12 Aug 2010

Pakistani officials fear cholera outbreak after massive flooding

After floods in northwest Pakistan have "already killed up to 1,200 people" and forced 2 million from their homes, authorities are now concerned about disease spread, the Associated Press reports.

2 Aug 2010

National Jewish Health receives $31M NIH contract to study skin infections associated with atopic dermatitis

The National Institute of Allergy and Infections Disease has awarded a five-year $31 million contract to National Jewish Health, which is leading a consortium of academic medical centers seeking to better understand skin infections associated with atopic dermatitis. The researchers will focus on antibiotic-resistant staphylococcus aureus (MRSA) infections and widespread viral infections of the skin, both of which are more prevalent among atopic dermatitis patients.

23 Jul 2010

NovaBay reports positive results from NVC-422 Phase 2a proof-of-concept clinical trial for impetigo

NovaBay Pharmaceuticals, Inc. today announced that its lead product candidate was safe and efficacious against the highly contagious skin infection impetigo in a Phase 2a proof-of-concept clinical trial. This dose-ranging study showed that the drug cleared impetigo infections, including those in the trial caused by a drug-resistant strain of bacteria called methicillin-resistant Staphylococcus aureus or MRSA. Impetigo afflicts approximately 1 million people, primarily infants and children, in the United States annually.

21 Jul 2010

NovaBay Pharmaceuticals issued Notice of Allowance for broad portfolio of anti-infective compounds

NovaBay Pharmaceuticals, Inc. announced today that it has received a Notice of Allowance from the United States Patent and Trademark Office on a patent application for a broad portfolio of anti-infective compounds, including NVC-612. The patent will broaden protection for NovaBay's first-in-class Aganocide family of compounds, which are designed to fight infections without causing drug resistance.

15 Jul 2010

Skin Infection News and Research

Forest Laboratories second quarter net sales increase 7.7% to $1,037.3 million

NovaBay to present two poster presentations at IDSA Annual Meeting

Persimmon Scientific to showcase antimicrobial nursing pads, hypoallergenic diaper liners at 8th ABC Kids Expo

Isogenica, NovaBiotics to accelerate the development of peptide anti-infective technology

Islamic Relief USA provides $20 million medical aid to Pakistan

NovaBay Pharmaceuticals delivers poster presentations on Aganocide compound at ICAAC Conference

Rib-X Pharmaceuticals presents positive preclinical data for delafloxacin at ICAAC Conference

NovaBay Pharmaceuticals to deliver new data on Aganocide compounds at ICAAC Conference

Lytix Biopharma granted Hungarian approval for Lytixar Phase IIa clinical trial in Gram positive skin infections

Neutralizing key toxin associated with Staph aureus bacteria reduces severity of skin and soft-tissue damage

Media examine floods' impact in Pakistan

Scientists report frog skin contains new genera of antibiotics

Diarrhea, skin diseases increase among children in flood-affected areas of Pakistan: Survey

NanoViricides' anti-Herpes drug candidates demonstrate significant efficacy in cell culture studies

NovaBay second-quarter net loss increases to $1.2 million

Hospital staph infection rate drops as national prevention effort steps up

Pakistani officials fear cholera outbreak after massive flooding

National Jewish Health receives $31M NIH contract to study skin infections associated with atopic dermatitis

NovaBay reports positive results from NVC-422 Phase 2a proof-of-concept clinical trial for impetigo

NovaBay Pharmaceuticals issued Notice of Allowance for broad portfolio of anti-infective compounds

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News